Clinical and Genetic Factors Associated with Multivessel Coronary Artery Disease: A Cross-Sectional Study of CYP2C19 Polymorphisms and Metabolic Comorbidities Authors: Nan Cai, Youqian Li, Jingfeng Liu, Haifeng Hong, Changjing Huang, Hanlin Li, Mingrui Li, Junyin Peng Published: 2026 ABSTRACT BackgroundMulti-vessel coronary artery disease (MVCD), defined as stenosis affecting ≥2 major coronary arteries, confers poor clinical outcomes in patients with coronary artery disease (CAD). Cytochrome P450 2C19 (CYP2C19) CYP2C19 participates in lipid metabolism and inflammatory regulation, which may be associated with individual variations in the severity of coronary artery lesions. This study aimed to explore the clinical and genetic factors associated with MVCD focusing on CYP2C19 polymorphisms and chronic metabolic diseases.MethodsThis single‑center cross‑sectional study enrolled 4124 patients with angiographically confirmed CAD, who were divided into single‑vessel CAD (n=846) and MVCD (n=3278) groups. Baseline clinical data and CYP2C19 genotypes were collected. The chi-square test, Hardy-Weinberg equilibrium test, and logistic regression analyses were performed for statistical evaluation.ResultsHigher prevalences of hypertension, type 2 diabetes mellitus, and dyslipidemia were observed in MVCD patients. CYP2C19*2 (rs4244285, 681G>A) and *3 (rs4986893, 636G>A) allele frequencies were markedly elevated in the MVCD group. Logistic regression analysis confirmed that hypertension (odds ratio (OR)=1.485, 95% confidence interval (CI): 1.267‑1.740, p<0.001), T2DM (OR=2.441, 95% CI: 2.006‑2.970, p<0.001), dyslipidemia (OR=1.313, 95% CI: 1.097‑1.572, p=0.003), and CYP2C19 poor metabolizer (*2/*2, *2/*3 and *3/*3 genotypes) status (OR=1.744, 95% CI: 1.360‑2.237, p<0.001) was independently associated with MVCD. The combined impaired CYP2C19 metabolic phenotype (intermediate (*1/*2 and *1/*3 genotypes) plus poor metabolizers) was also independently correlated with MVCD (adjusted OR=1.285, 95% CI: 1.095–1.508, p=0.002).ConclusionClinical metabolic comorbidities and the combined impaired CYP2C19 metabolic phenotype are associated with MVCD. These findings may provide valuable reference for risk assessment of severe CAD. Introduction Coronary artery disease (CAD) is the most prevalent type of atherosclerotic cardiovascular disease and continues to rank as the primary cause of global mortality and premature death, placing an enormous economic and medical burden on global public health.1,2 With the continuous changes in dietary structure, aging population and lifestyle, the incidence and severity of CAD have shown a persistent upward trend, especially in Asian populations.3 Multi-vessel coronary artery disease (MVCD), a severe subtype of CAD, is defined as atherosclerotic stenosis involving two or more major coronary branches.4,5 Compared with single-vessel lesions, MVCD is characterized by more extensive vascular lesions, more severe inflammatory responses, higher rates of in-stent restenosis, and significantly increased risks of acute myocardial infarction and long-term major adverse cardiovascular events.6–8 Despite standardized clinical intervention, MVCD patients still have poor long-term prognosis and high recurrence rates, making it a key and difficult point in the clinical management of CAD.9,10 Traditional metabolic risk factors, including hypertension, type 2 diabetes mellitus (T2DM), and dyslipidemia, are recognized as core contributors to coronary atherosclerosis.11–13 These metabolic conditions may induce vascular endothelial damage and lipid accumulation, potentially facilitating the formation of atherosclerotic plaques and the occurrence of CAD. However, emerging clinical studies have found significant individual differences in coronary lesion severity among patients with similar metabolic risk profiles, indicating that in addition to conventional clinical risk factors being related to MVCD, genetic susceptibility factors may play a vital role. Cytochrome P450 2C19 (CYP2C19) is a key member of the human cytochrome P450 superfamily, and is involved in endogenous lipid metabolism14 and the biotransformation of some drugs.15 CYP2C19 participates in arachidonic acid metabolic processes and influences inflammatory mediator secretion, with inflammation being critical to the formation, advancement and fracture of atherosclerotic plaques.16,17 Functional variants of CYP2C19 reduce enzyme activity, disturb lipid homeostasis and amplify vascular inflammatory injury, which may promote diffuse atherosclerotic plaque formation and contribute to more extensive coronary involvement. Two prevalent single-nucleotide polymorphisms (SNPs) in CYP2C19 are rs4244285 (681G>A, *2) and rs4986893 (636G>A, *3).18,19 These genetic variants contribute to six CYP2C19 genotypes, namely *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*320. Correspondingly, three metabolic phenotypes were classified: extensive metabolizer (EM) for the *1/*1 genotype, intermediate metabolizer (IM) including the *1/*2 and *1/*3 genotypes, and poor metabolizer (PM) covering the *2/*2, *2/*and *3/*3 genotypes.20,21 Several mechanistic studies have confirmed that CYP2C19 genetic variants can disrupt lipid homeostasis, aggravate vascular endothelial inflammatory damage, accelerate atherosclerotic plaque formation and maturation, and ultimately affect the severity of coronary artery lesions.22,23 Although prior works have investigated CYP2C19 polymorphisms and coronary events or drug response, large‑sample clinical evidence evaluating the independent association between CYP2C19 metabolic phenotypes and multi‑vessel coronary artery disease, together with their joint effect with chronic metabolic diseases, remains limited. Moreover, the relationship between CYP2C19 genetic variations and the combined effect with traditional chronic metabolic diseases on MVCD has not yet been fully clarified. Currently, there is currently limited comprehensive clinical evidence regarding genetic correlation of severe CAD. The aim of this study was to systematically compare the differences in CYP2C19 genotypes, alleles, and metabolic phenotype distribution between single-vessel and multi-vessel CAD patients, and further integrate common chronic metabolic comorbidities to screen independent clinical and genetic factors associated with MVCD. Materials and Methods Study Design and Participants This study adopted a large-scale single-center cross-sectional design. This study consecutively enrolled patients who were diagnosed with CAD and underwent coronary angiography at the Meizhou People’s Hospital from December 2019 to November 2025. Coronary angiograms were interpreted by two experienced interventional cardiologists. Patients who met all the following criteria were enrolled in the present study: (1) age ≥18 years; (2) clinically definitively diagnosed coronary artery disease; (3) completed standardized coronary angiography examination with clear and identifiable coronary lesion results; (4) complete baseline clinical data, laboratory lipid indicators, and CYP2C19 genotyping data; and (5) complete follow-up and medical record information without missing key variables. Patients were excluded if they met any of the following exclusion criteria: (1) a history of percutaneous coronary intervention, coronary artery bypass grafting, or other coronary revascularization procedures; (2) severe organic diseases, including end-stage heart failure, severe hepatic and renal insufficiency, and severe autoimmune diseases; (3) acute myocardial infarction, severe myocarditis, or other acute critical cardiovascular diseases at admission; (4) missing serum lipid test results, or unqualified CYP2C19 genotyping data; and (5) patients with incomplete medical records. A total of 4124 eligible patients were consecutively enrolled in this study. All participants underwent standardized coronary angiography to confirm the presence, location, and number of coronary artery lesions. The present study was conducted in accordance with the principles of the Declaration of Helsinki. All participants provided informed consent, and the study protocol was approved by the Ethics Committee of the Meizhou People’s Hospital. Grouping Criteria Based on the number of diseased coronary vessels confirmed by angiography, all patients were divided into the single-vessel CAD and MVCD groups. Single-vessel CAD was defined as ≥50% stenosis occurring in only one major coronary artery, including the left anterior descending artery (LAD), circumflex artery (LCX), or right coronary artery (RCA). MVCD was defined as the presence of significant stenosis (≥50%) in two or more major coronary arteries, including two-vessel and three-vessel lesions. Patients with isolated left main coronary artery stenosis or lesions involving the left main artery were excluded from the present study; only lesions located in the LAD, LCX, and RCA were considered for single‑vessel and MVCD grouping. Finally, 846 patients were included in the single-vessel CAD group and 3278 patients in the MVCD group, respectively. Collection of Clinical Baseline Data General baseline information and clinical data of all participants were systematically collected, including gender, age, body mass index (BMI), smoking history, and alcohol consumption history. According to clinical classification criteria, age was categorized as <60 years and ≥60 years; BMI was classified into underweight (<18.5 kg/m2), normal weight (18.5–23.9 kg/m2), and overweight (≥24.0 kg/m2).24,25 Participants were regarded as smokers if they had smoked ≥1 cigarette daily for 1 year or longer, or quit smoking within the latest 6 months. Alcohol consumption refers to drinking alcoholic beverages at least weekly for six consecutive months and above. Comorbidities included hypertension, T2DM, and dyslipidemia. Hypertension was defined as a resting systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or a confirmed history of hypertension with regular antihypertensive medication use.26 T2DM was diagnosed when random blood glucose was ≥11.1 mmol/L, fasting plasma glucose was ≥7.0 mmol/L, or 2-hour postprandial glucose was ≥11.1 mmol/L.27 In accordance with the National Guidelines for the Prevention and Control of Dyslipidemia in Chinese Adults, individuals are defined as having dyslipidemia if they meet any of the following lipid level cut-off values: (1) total cholesterol (TC) ≥6.22 mmol/L), (2) triglyceride (TG) ≥2.26 mmol/L, or (3) low-density lipoprotein-cholesterol (LDL-C) ≥4.14 mmol/L.24,28 Detection of CYP2C19 Genotypes and Phenotypes Classification CYP2C19 genotyping was performed on peripheral blood genomic DNA samples from the enrolled participants, adopting a previously reported experimental approach.29,30 Genomic DNA was extracted from peripheral whole blood using a QIAamp DNA Blood Mini Kit (Qiagen GmbH, North Rhine-Westphalia, Germany) according to the manufacturer’s instructions. The detection of CYP2C19 *2 and *3 variant alleles were detected using a commercial genotyping kit from BaiO Technology Co., Ltd. (Shanghai, China). Genotyping experiments were performed following the kit manufacturer’s protocol. Negative controls were included in each batch of detection. Samples with ambiguous genotyping results were retested; only qualified genotyping data were retained for subsequent analysis. The CYP2C19 gene polymorphisms, including *1, *2, and *3 alleles were detected. According to the detected genotypes, participants were divided into six genotype subgroups: *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3. Based on the functional characteristics of CYP2C19 genetic variants, patients were further classified into three metabolic phenotypes: extensive metabolizer (EM, *1/*1), intermediate metabolizer (IM, *1/*2, *1/*3), and poor metabolizer (PM, *2/*2, *2/*3, *3/*3). For subsequent risk analysis, the IM and PM phenotypes were combined as impaired metabolic phenotypes to explore the association between abnormal CYP2C19 metabolic function and multi-vessel coronary lesions. Statistical Analysis Statistical processing of the collected data was carried out using SPSS version 26.0 (IBM Inc., United States). Differences in continuous variables were assessed using Student’s t-test or Mann–Whitney U-test. Categorical variables were compared using the χ2 test. The Hardy-Weinberg equilibrium (HWE) test was applied to the overall population and each subgroup to evaluate the genetic representativeness of the enrolled study sample; a p>0.05 indicated a good population genetic balance. To identify the factors associated with MVCD, logistic regression analysis was initially performed to screen potential influencing factors. Age, gender, BMI, smoking history, alcohol abuse, hypertension, T2DM, and dyslipidemia were all entered into the multivariable logistic regression model, because these factors are widely‑recognized traditional risk factors for coronary artery disease. Variance inflation factors were calculated to detect multicollinearity, and the Hosmer‑Lemeshow test was used to evaluate model goodness‑of‑fit. Intermediate and poor metabolizers were combined as impaired metabolic phenotypes because both categories represent reduced CYP2C19 enzyme function, consistent with widely adopted grouping strategies in existing pharmacogenetic and cardiovascular studies. p<0.05 was considered statistically significant. Results Baseline Clinical Characteristics of the Study Population A total of 4124 patients with CAD were enrolled in the present study, with 2055 male patients (49.8%) and 2069 female patients (50.2%), showing a balanced gender distribution. In terms of age composition, the majority of patients were aged ≥60 years, accounting for 71.2% (2936/4124) of the total cohort, and 28.8% (1188/4124) of the patients were aged < 60 years. Regarding BMI classification, 3.9% (159/4124) of the patients were underweight, 47.1% (1942/4124) had normal weight, and 49.1% (2023/4124) were overweight. Regarding lifestyle-related risk factors, 21.0% (866/4124) of the patients had a history of smoking, and only 5.2% (213/4124) reported a history of alcohol consumption, indicating a low prevalence of long-term drinking in the study population. Hypertension was the most common chronic disease comorbidity, affecting 61.3% (2528/4124) of the patients. A total of 31.2% (1286/4124) of the patients were diagnosed with T2DM and 29.5% (1217/4124) had dyslipidemia. The median levels of serum lipid indicators in the overall population were as follows: TC 4.72 mmol/L (interquartile range [IQR]: 3.95–5.56 mmol/L), TG 1.45 mmol/L (IQR: 1.06–2.07 mmol/L), and LDL-C 2.68 mmol/L (IQR: 2.09–3.30 mmol/L). Detailed baseline characteristics of the study cohort are presented in Table 1.Table 1Baseline Characteristics of the Included Study CohortCharacteristicsTotal (n=4124)Gender Male, n (%)2055 (49.8%) Female, n (%)2069 (50.2%)Age (years) <60, n (%)1188 (28.8%) ≥60, n (%)2936 (71.2%)BMI (kg/m2) Underweight, n (%)159 (3.9%) Normal weight, n (%)1942 (47.1%) Overweight, n (%)2023 (49.1%)History of smoking No, n (%)3258 (79.0%) Yes, n (%)866 (21.0%)History of alcohol consumption No, n (%)3911 (94.8%) Yes, n (%)213 (5.2%)Hypertension No, n (%)1596 (38.7%) Yes, n (%)2528 (61.3%)T2DM No, n (%)2838 (68.8%) Yes, n (%)1286 (31.2%)Levels of serum lipid TC, mmol/L, median (IQR)4.72 (3.95, 5.56) TG, mmol/L, median (IQR)1.45 (1.06, 2.07) LDL-C, mmol/L, median (IQR)2.68 (2.09, 3.30)Dyslipidemia No, n (%)2907 (70.5%) Yes, n (%)1217 (29.5%)Abbreviations: BMI, body mass index; T2DM, type 2 diabetes mellitus; TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein-cholesterol; IQR, interquartile range. Table 1Baseline Characteristics of the Included Study CohortCharacteristicsTotal (n=4124)Gender Male, n (%)2055 (49.8%) Female, n (%)2069 (50.2%)Age (years) <60, n (%)1188 (28.8%) ≥60, n (%)2936 (71.2%)BMI (kg/m2) Underweight, n (%)159 (3.9%) Normal weight, n (%)1942 (47.1%) Overweight, n (%)2023 (49.1%)History of smoking No, n (%)3258 (79.0%) Yes, n (%)866 (21.0%)History of alcohol consumption No, n (%)3911 (94.8%) Yes, n (%)213 (5.2%)Hypertension No, n (%)1596 (38.7%) Yes, n (%)2528 (61.3%)T2DM No, n (%)2838 (68.8%) Yes, n (%)1286 (31.2%)Levels of serum lipid TC, mmol/L, median (IQR)4.72 (3.95, 5.56) TG, mmol/L, median (IQR)1.45 (1.06, 2.07) LDL-C, mmol/L, median (IQR)2.68 (2.09, 3.30)Dyslipidemia No, n (%)2907 (70.5%) Yes, n (%)1217 (29.5%)Abbreviations: BMI, body mass index; T2DM, type 2 diabetes mellitus; TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein-cholesterol; IQR, interquartile range. Baseline Characteristics of the Included Study Cohort Abbreviations: BMI, body mass index; T2DM, type 2 diabetes mellitus; TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein-cholesterol; IQR, interquartile range. Coronary Artery Lesion Distribution and Comparison of Clinical Characteristics Between Single-Vessel and Multi-Vessel CAD Groups The anatomical distribution of the coronary artery lesions in the overall cohort was analyzed, and the detailed lesion site distribution is illustrated in Figure 1. Among the 4124 CAD patients, three-vessel disease was the most prevalent lesion type (53.7%, n=2215) of the total population, followed by combined lesion of LAD and RCA lesions with a proportion of 17.5% (n=721), and single-vessel lesions of LAD (16.2%, n=669). In addition, the proportion of combined LAD and LCX lesions was 7.1% (n=293). Isolated RCA lesions, isolated LCX lesions, and combined LCX and RCA lesions were relatively rare, with proportions of 3.0% (n=125), 1.3% (n=52), and 1.2% (n=49), respectively.Figure 1The distribution of the lesion sites in the coronary arteries.A bar graph showing distribution of coronary artery lesion sites across vessel combinations. The distribution of the lesion sites in the coronary arteries. Subsequently, all enrolled patients were stratified into the single-vessel CAD (n=846) and MVCD (n=3278) groups according to the number of coronary artery lesion vessels. Comparative analysis of clinical characteristics between the two groups showed no significant differences in gender distribution, age composition, BMI classification, smoking history, and alcohol consumption history (all p>0.05). Specifically, the proportion of male was 49.9% in the single-vessel group and 49.8% in the MVCD group (χ2=0.001, p=1.000); the proportion of elderly patients (≥60 years) was 69.1% and 72.7% in the two groups, respectively (χ2=2.168, p=0.148). Significant inter-group differences were observed in the prevalence of chronic comorbidities (all p< 0.001). The MVCD group exhibited a significantly higher rate of hypertension (63.7% vs. 52.0%, χ2=38.722), T2DM (34.8% vs 17.0%, χ2=99.475), and dyslipidemia (31.0% vs 23.9%, χ2=16.236) than the single-vessel CAD group. These results indicate that patients with multi-vessel coronary lesions had a higher burden of metabolic and cardiovascular comorbidities. Detailed comparative data are presented in Table 2.Table 2Comparison of Clinical Features Between Single-Vessel CAD and MVCD GroupsVariablesSingle-Vessel CAD Group (n=846)MVCD Group (n=3278)p (χ2)Gender Male, n (%)422 (49.9%)1633 (49.8%)1.000(χ2=0.001) Female, n (%)424 (50.1%)1645 (50.2%)Age (years) <60, n (%)261 (30.9%)927 (28.3%)0.148(χ2=2.168) ≥60, n (%)585 (69.1%)2351 (72.7%)BMI (kg/m2) Underweight, n (%)43 (5.1%)116 (3.5%)0.108(χ2=4.462) Normal weight, n (%)398 (47.0%)1544 (47.1%) Overweight, n (%)405 (47.9%)1618 (49.4%)History of smoking No, n (%)671 (79.3%)2587 (78.9%)0.813(χ2=0.063) Yes, n (%)175 (20.7%)691 (21.1%)History of alcohol consumption No, n (%)802 (94.8%)3109 (94.8%)1.000(χ2=0.003) Yes, n (%)44 (5.2%)169 (5.2%)Hypertension No, n (%)406 (48.0%)1190 (36.3%)<0.001(χ2=38.722) Yes, n (%)440 (52.0%)2088 (63.7%)T2DM No, n (%)702 (83.0%)2136 (65.2%)<0.001(χ2=99.475) Yes, n (%)144 (17.0%)1142 (34.8%)Dyslipidemia No, n (%)644 (76.1%)2263 (69.0%)<0.001(χ2=16.236) Yes, n (%)202 (23.9%)1015 (31.0%)Abbreviations: CAD, coronary artery disease; MVCD, multi-vessel coronary artery disease; BMI, body mass index; T2DM, type 2 diabetes mellitus. Table 2Comparison of Clinical Features Between Single-Vessel CAD and MVCD GroupsVariablesSingle-Vessel CAD Group (n=846)MVCD Group (n=3278)p (χ2)Gender Male, n (%)422 (49.9%)1633 (49.8%)1.000(χ2=0.001) Female, n (%)424 (50.1%)1645 (50.2%)Age (years) <60, n (%)261 (30.9%)927 (28.3%)0.148(χ2=2.168) ≥60, n (%)585 (69.1%)2351 (72.7%)BMI (kg/m2) Underweight, n (%)43 (5.1%)116 (3.5%)0.108(χ2=4.462) Normal weight, n (%)398 (47.0%)1544 (47.1%) Overweight, n (%)405 (47.9%)1618 (49.4%)History of smoking No, n (%)671 (79.3%)2587 (78.9%)0.813(χ2=0.063) Yes, n (%)175 (20.7%)691 (21.1%)History of alcohol consumption No, n (%)802 (94.8%)3109 (94.8%)1.000(χ2=0.003) Yes, n (%)44 (5.2%)169 (5.2%)Hypertension No, n (%)406 (48.0%)1190 (36.3%)<0.001(χ2=38.722) Yes, n (%)440 (52.0%)2088 (63.7%)T2DM No, n (%)702 (83.0%)2136 (65.2%)<0.001(χ2=99.475) Yes, n (%)144 (17.0%)1142 (34.8%)Dyslipidemia No, n (%)644 (76.1%)2263 (69.0%)<0.001(χ2=16.236) Yes, n (%)202 (23.9%)1015 (31.0%)Abbreviations: CAD, coronary artery disease; MVCD, multi-vessel coronary artery disease; BMI, body mass index; T2DM, type 2 diabetes mellitus. Comparison of Clinical Features Between Single-Vessel CAD and MVCD Groups Abbreviations: CAD, coronary artery disease; MVCD, multi-vessel coronary artery disease; BMI, body mass index; T2DM, type 2 diabetes mellitus. Distribution of CYP2C19 Genotypes, Alleles and Phenotypes The CYP2C19 genotypes, alleles, and phenotype distributions were compared between the two CAD groups, and the Hardy-Weinberg equilibrium (HWE) test verified that the genotype distribution of the overall population, single-vessel group and MVCD group all conformed to the genetic equilibrium (all p>0.05), suggesting the representativeness of the study sample. Among all the enrolled patients, the dominant genotypes were *1/*1 (36.8%, 1516/4124) and *1/*2 (39.1%, 1612/4124). Significant differences in genotypes distribution were detected between the two groups. The frequency of the *1/*1 wild-type genotype was markedly lower in the MVCD group than that in the single-vessel group (35.6% vs 41.4%, χ2=9.733, p=0.002). In contrast, the MVCD group had significantly higher frequencies of *1/*3 (8.1% vs 5.0%, χ2=9.342, p=0.002), *2/*2 (12.8% vs 8.7%, χ2=10.403, p=0.001), and *2/*3 genotypes (4.7% vs 3.0%, χ2=4.775, p=0.029). No significant inter-group difference was found in the *3/*3 genotype distribution (χ2=0.261, p=0.780). The *1/*2 genotype was not significantly different between the two groups (χ2=2.837, p=0.097). The *1 wild-type allele was the most prevalent in the overall population (60.0%, 4950/8248), followed by the *2 allele (33.7%, 2776/8248), and the *3 allele (6.3%, 522/8248). Further inter-group comparison revealed that the single-vessel group had a higher *1 allele frequency (64.7% vs 58.8%, χ2=19.120, p<0.001), while the MVCD group had higher frequencies of *2 (34.3% vs 31.0%, χ2=6.585, p=0.011) and *3 alleles (6.8% vs 4.3%, χ2=14.570, p<0.001). Based on CYP2C19 metabolic phenotypes, the study population was divided into extensive metabolizer (EM), intermediate metabolizer (IM) and poor metabolizer (PM). The proportion of EM was significantly lower in the MVCD group (35.6% vs 41.4%, χ2=9.733, p=0.002), and the PM phenotype was significantly more common in the MVCD group (17.9% vs 12.1%, χ2=16.694, p<0.001). No significant difference in the IM phenotype distribution was observed between the two groups (46.5% vs 46.6%, χ2=0.002, p=0.969). The detailed genetic distribution data are shown in Table 3.Table 3Comparison of the CYP2C19 Genotypes and Alleles Between Patients with Single-Vessel CAD and MVCDCYP2C19 Genotypes, Alleles, and PhenotypesTotal (n=4124)Single-Vessel CAD Group (n=846)MVCD Group (n=3278)p (χ2)Genotypes*1/*11516 (36.8%)350 (41.4%)1166 (35.6%)0.002 (χ2=9.733)*1/*21612 (39.1%)352 (41.6%)1260 (38.4%)0.097 (χ2=2.837)*1/*3306 (7.4%)42 (5.0%)264 (8.1%)0.002 (χ2=9.342)*2/*2493 (12.0%)74 (8.7%)419 (12.8%) 0.001 (χ2=10.403)*2/*3178 (4.3%)25 (3.0%)153 (4.7%)0.029 (χ2=4.775)*3/*319 (0.5%)3 (0.4%)16 (0.5%)0.780 (χ2=0.261)Alleles*14950 (60.0%)1094 (64.7%)3856 (58.8%)<0.001 (χ2=19.120)*22776 (33.7%)525 (31.0%)2251 (34.3%)0.011 (χ2=6.585)*3522 (6.3%)73 (4.3%)449 (6.8%)<0.001 (χ2=14.570)HWE, p(χ2)p=0.356 (χ2=4.385)p=0.511 (χ2=3.290)p=0.148 (χ2=6.771)PhenotypesExtensive metabolizer1516 (36.8%)350 (41.4%)1166 (35.6%)0.002 (χ2=9.733)Intermediate metabolizer1918 (46.5%)394 (46.6%)1524 (46.5%)0.969 (χ2=0.002)Poor metabolizer690 (16.7%)102 (12.1%)588 (17.9%)<0.001 (χ2=16.694)Abbreviations: CYP2C19, cytochrome P450 2C19; CAD, coronary artery disease; MVCD, multi-vessel coronary artery disease; HWE, Hardy Weinberg Equilibrium. Table 3Comparison of the CYP2C19 Genotypes and Alleles Between Patients with Single-Vessel CAD and MVCDCYP2C19 Genotypes, Alleles, and PhenotypesTotal (n=4124)Single-Vessel CAD Group (n=846)MVCD Group (n=3278)p (χ2)Genotypes*1/*11516 (36.8%)350 (41.4%)1166 (35.6%)0.002 (χ2=9.733)*1/*21612 (39.1%)352 (41.6%)1260 (38.4%)0.097 (χ2=2.837)*1/*3306 (7.4%)42 (5.0%)264 (8.1%)0.002 (χ2=9.342)*2/*2493 (12.0%)74 (8.7%)419 (12.8%) 0.001 (χ2=10.403)*2/*3178 (4.3%)25 (3.0%)153 (4.7%)0.029 (χ2=4.775)*3/*319 (0.5%)3 (0.4%)16 (0.5%)0.780 (χ2=0.261)Alleles*14950 (60.0%)1094 (64.7%)3856 (58.8%)<0.001 (χ2=19.120)*22776 (33.7%)525 (31.0%)2251 (34.3%)0.011 (χ2=6.585)*3522 (6.3%)73 (4.3%)449 (6.8%)<0.001 (χ2=14.570)HWE, p(χ2)p=0.356 (χ2=4.385)p=0.511 (χ2=3.290)p=0.148 (χ2=6.771)PhenotypesExtensive metabolizer1516 (36.8%)350 (41.4%)1166 (35.6%)0.002 (χ2=9.733)Intermediate metabolizer1918 (46.5%)394 (46.6%)1524 (46.5%)0.969 (χ2=0.002)Poor metabolizer690 (16.7%)102 (12.1%)588 (17.9%)<0.001 (χ2=16.694)Abbreviations: CYP2C19, cytochrome P450 2C19; CAD, coronary artery disease; MVCD, multi-vessel coronary artery disease; HWE, Hardy Weinberg Equilibrium. Comparison of the CYP2C19 Genotypes and Alleles Between Patients with Single-Vessel CAD and MVCD Abbreviations: CYP2C19, cytochrome P450 2C19; CAD, coronary artery disease; MVCD, multi-vessel coronary artery disease; HWE, Hardy Weinberg Equilibrium. Associated Factors for MVCD Univariate and multivariate logistic regression analyses were performed to identify independent factors associated with MVCD, with single-vessel CAD as the control outcome. Univariate logistic regression analysis showed that hypertension, T2DM, dyslipidemia, and CYP2C19 poor‑metabolizer phenotype, and the impaired metabolic phenotypes (IM plus PM) were significantly associated with the occurrence of MVCD (all p<0.05). In contrast, gender, age, BMI status, smoking history, and alcohol consumption history showed no significant correlation with MVCD (all p>0.05) (Table 4).Table 4Logistic Regression Analysis of Risk Factors for MVCDVariablesUnivariate OR (95% CI)p valuesMultivariate OR (95% CI)p valuesGender (Male vs Female)0.997 (0.857–1.160)0.9731.060 (0.880–1.275)0.540Age (≥60 vs <60 years old)1.132 (0.960–1.334)0.1411.102 (0.923–1.315)0.285BMI (kg/m2) Normal weight1.000 (reference)–1.000 (reference)– Underweight0.695 (0.482–1.004)0.0520.855 (0.588–1.243)0.412 Overweight1.030 (0.882–1.202)0.7100.935 (0.796–1.098)0.414History of smoking (Yes vs No)1.024 (0.850–1.234)0.8021.084 (0.861–1.364)0.492History of alcoholism (Yes vs No)0.991 (0.705–1.393)0.9580.985 (0.681–1.426)0.937Hypertension (Yes vs No)1.619 (1.390–1.886)<0.0011.485 (1.267–1.740)<0.001T2DM (Yes vs No)2.606 (2.149–3.162)<0.0012.441 (2.006–2.970)<0.001Dyslipidemia (Yes vs No)1.430 (1.201–1.703)<0.0011.313 (1.097–1.572)0.003CYP2C19 phenotypes Extensive metabolizer1.000 (reference)–1.000 (reference)– Intermediate metabolizer1.161 (0.987–1.367)0.0721.171 (0.990–1.385)0.066 Poor metabolizer1.730 (1.359–2.204)<0.0011.744 (1.360–2.237)<0.001 Intermediate metabolizer + Poor metabolizer1.278 (1.095–1.492)0.0021.285 (1.095–1.508)0.002Abbreviations: MVCD, multi-vessel coronary artery disease; T2DM, type 2 diabetes mellitus; BMI, body mass index; OR, odds ratio; CI, confidence interval. Table 4Logistic Regression Analysis of Risk Factors for MVCDVariablesUnivariate OR (95% CI)p valuesMultivariate OR (95% CI)p valuesGender (Male vs Female)0.997 (0.857–1.160)0.9731.060 (0.880–1.275)0.540Age (≥60 vs <60 years old)1.132 (0.960–1.334)0.1411.102 (0.923–1.315)0.285BMI (kg/m2) Normal weight1.000 (reference)–1.000 (reference)– Underweight0.695 (0.482–1.004)0.0520.855 (0.588–1.243)0.412 Overweight1.030 (0.882–1.202)0.7100.935 (0.796–1.098)0.414History of smoking (Yes vs No)1.024 (0.850–1.234)0.8021.084 (0.861–1.364)0.492History of alcoholism (Yes vs No)0.991 (0.705–1.393)0.9580.985 (0.681–1.426)0.937Hypertension (Yes vs No)1.619 (1.390–1.886)<0.0011.485 (1.267–1.740)<0.001T2DM (Yes vs No)2.606 (2.149–3.162)<0.0012.441 (2.006–2.970)<0.001Dyslipidemia (Yes vs No)1.430 (1.201–1.703)<0.0011.313 (1.097–1.572)0.003CYP2C19 phenotypes Extensive metabolizer1.000 (reference)–1.000 (reference)– Intermediate metabolizer1.161 (0.987–1.367)0.0721.171 (0.990–1.385)0.066 Poor metabolizer1.730 (1.359–2.204)<0.0011.744 (1.360–2.237)<0.001 Intermediate metabolizer + Poor metabolizer1.278 (1.095–1.492)0.0021.285 (1.095–1.508)0.002Abbreviations: MVCD, multi-vessel coronary artery disease; T2DM, type 2 diabetes mellitus; BMI, body mass index; OR, odds ratio; CI, confidence interval. Logistic Regression Analysis of Risk Factors for MVCD Abbreviations: MVCD, multi-vessel coronary artery disease; T2DM, type 2 diabetes mellitus; BMI, body mass index; OR, odds ratio; CI, confidence interval. After adjustment for potential confounders in multivariate logistic regression, hypertension (odds ratio (OR)=1.485, 95% confidence interval (CI): 1.267‑1.740, p<0.001), T2DM (OR=2.441, 95% CI: 2.006‑2.970, p<0.001), and dyslipidemia (OR=1.313, 95% CI: 1.097‑1.572, p=0.003) remained independent risk factors for MVCD. When metabolic phenotypes were analysed separately, poor‑metabolizer status was independently associated with MVCD (OR=1.744, 95% CI: 1.360‑2.237, p<0.001), while intermediate‑metabolizer status showed no statistically‑significant independent correlation (OR=1.171, 95% CI: 0.990‑1.385, p=0.066). The combined impaired‑metabolizer phenotype (IM plus PM) was also independently correlated with MVCD (OR=1.285, 95% CI: 1.095‑1.508, p=0.002) (Table 4). Discussion The present large-scale single-center cross-sectional study enrolled 4124 patients with clinically confirmed CAD to comprehensively explore the clinical and genetic risk factors for MVCD. By systematically comparing the baseline clinical profiles and CYP2C19 genotypic and phenotypic characteristics between the single-vessel and multi-vessel CAD subgroups, our study yielded two core novel findings. First, consistent with classical cardiovascular research conclusions, hypertension, T2DM, and dyslipidemia were verified as independent associated factors of MVCD in this large Chinese cohort. Second, impaired CYP2C19 metabolic phenotypes (intermediate and poor metabolizers) were identified as an independent genetic factors associated with multi-vessel coronary lesions, even after fully adjusting for traditional demographic and metabolic confounding variables. Collectively, these results highlight that the MVCD is correlated with clinical metabolic abnormalities and genetic susceptibility. Traditional metabolic comorbidities have long been recognized as pivotal drivers of coronary atherosclerosis. Our study further consolidates and extends this clinical consensus.5,31 Long-term uncontrolled hypertension induces persistent mechanical damage to vascular endothelial cells, increases arterial wall permeability, and promotes the infiltration of inflammatory cells and lipid deposition, which accelerates the formation and proliferation of atherosclerotic plaques.32 Chronic hyperglycemia in T2DM promotes the development of atherosclerosis through mechanisms such as endothelial dysfunction, oxidative stress, formation of advanced glycation end products (AGEs), and chronic inflammation.33,34 As a core pathological basis of atherosclerosis, dyslipidemia, characterized by elevated TC, TG and LDL-C levels directly promotes lipid foam cell formation and plaque maturation.35 In this study, the MVCD group had a significantly higher prevalence of hypertension, T2DM, and dyslipidemia than patients with single-vessel lesions, and multivariate logistic regression analysis confirmed that these three metabolic diseases were independent risk factors for MVCD. These findings are highly consistent with those of previous epidemiological studies, which have demonstrated that aggregated metabolic abnormalities are closely correlated with lesion severity, lesion diffusion and poor prognosis of CAD. Therefore, standardized, long-term, and intensive management of blood pressure, blood glucose and blood lipid levels remains a fundamental clinical strategy to prevent MVCD. Beyond modifiable clinical metabolic risk factors, genetic susceptibility is an indispensable non-modifiable factor that affects individual differences in coronary lesion severity.36,37 Several studies have investigated the relationship between CYP2C19 gene polymorphisms and CAD. Previous research by Chen et al indicated that CYP2C19 functional deficiency caused by gene polymorphisms serves as a risk factor for premature coronary artery disease (PCAD).38 Likewise, Hokimoto et al illustrated that the CYP2C19 PM metabolic phenotype may elevate the susceptibility to CAD in females.39 Further evidence from Han et al confirmed that the CYP2C19 PM phenotype is an independent risk factor for premature myocardial infarction (PMI).40 CYP2C19 loss-of-function may be associated with CAD in hypertensive patients41 and T2DM patients.42 Our study focused on the clinical value of CYP2C19 genetic polymorphisms in MVCD. The CYP2C19 gene exhibits obvious ethnic genetic heterogeneity: loss-of-function mutations (*2, *3 alleles) are rare in Western populations but have a high carrier rate in East Asian populations, including Chinese individuals, which explains the distinct genetic susceptibility to severe CAD in Asian groups.42–44 In our cohort, genetic distribution analysis showed that the wild-type *1 allele and extensive metabolizer phenotype dominated in single-vessel CAD patients, whereas the frequencies of *2 and *3 alleles and impaired metabolic phenotypes were significantly increased in the MVCD subgroup. After adjusting for all clinical confounding factors, CYP2C19 intermediate plus poor metabolic phenotypes remained independently associated with MVCD. Of note, the significant association observed for the combined impaired‑metabolizer group was mainly driven by poor metabolizers, given the lack of difference for intermediate metabolizers between groups. Furthermore, the modest magnitude of the genetic effect and cross‑sectional design limit direct clinical inference. Mechanistically, the potential atherogenic effects of abnormal CYP2C19 function can be attributed to multiple biological pathways. As a key metabolic enzyme in the human body, CYP2C19 participates in the metabolism of endogenous lipids and inflammatory mediators.45 Loss-of-function mutations inhibit enzyme activity, disrupt systemic lipid homeostasis, and lead to the abnormal accumulation of lipid metabolites in the vascular wall.46 Meanwhile, CYP2C19 dysfunction can aggravate vascular endothelial inflammatory damage, upregulate the expression of pro-atherosclerotic cytokines, and promote the formation of diffuse, multi-site atherosclerotic plaques, ultimately increasing the risk of multi-vessel coronary lesions.23 This mechanistic evidence strongly supports our clinical statistical results and reveals the intrinsic genetic mechanism underlying the high severity of CAD in patients with CYP2C19 variants. The findings of this study provide important translational and clinical guiding significance for the precise management of CAD. In clinical practice, routine screening and standardized intervention for hypertension, T2DM, and dyslipidemia should be emphasized for all CAD patients to prevent MVCD. More importantly, this study proposes that CYP2C19 polymorphisms can be used as a auxiliary biomarker for risk stratification of CAD. Clinicians should recognize the high genetic susceptibility of patients carrying CYP2C19 mutant alleles and presenting impaired metabolic phenotypes, even with mild single-vessel lesions and well-controlled metabolic indicators, to severe CAD. These high-risk patients require intensified long-term follow-up, individualized lifestyle intervention and more rigorous risk monitoring, so as to achieve early prediction, early warning and early intervention of MVCD, and reduce the incidence of severe cardiovascular events. Several limitations of this study must be objectively acknowledged objectively to guide subsequent research. First, this was a single-center cross-sectional study. Although the sample size was large, the cross-sectional design can only confirm the correlation between variables and MVCD, but cannot determine the causal relationship and temporal sequence between CYP2C19 polymorphisms, metabolic diseases and multi-vessel coronary lesions. Future multi-center, prospective longitudinal cohort studies are required to further validate our conclusions and explore the causal mechanisms. Second, this study only detected the most common CYP2C19 *2 and *3 loss-of-function alleles in Chinese populations, while rare gene variants were not included in the analysis, which may have led to incomplete evaluation of genetic metabolic phenotypes. Third, we only focused on the correlation between baseline indicators and lesion severity, and did not further collect long-term follow-up data to analyze the relationship between combined clinical and genetic indicators for adverse cardiovascular outcomes. Finally, all participants were enrolled from a single regional hospital, which may have caused a certain selection bias and limited the generalizability of the research conclusions; further multi‑ethnic studies are needed before extending these conclusions to other ethnic groups. Conclusion In summary, this large-scale clinical study confirmed that hypertension, T2DM, dyslipidemia, and CYP2C19 impaired metabolic phenotypes are associated with MVCD in patients with CAD. CYP2C19 gene polymorphism is a vital genetic-related factor for MVCD. Although combining metabolic risk assessment with CYP2C19 phenotyping may hold potential clinical value, prospective studies are needed to validate these observations. The present findings add to the understanding of MVCD.